Literature DB >> 11125886

Marked immunosuppressive effects of the HIV-2 envelope protein in spite of the lower HIV-2 pathogenicity.

R Cavaleiro1, A E Sousa, A Loureiro, R M Victorino.   

Abstract

OBJECTIVE: HIV-1 envelope proteins have immunosuppressive properties and it is thought that they have a role in the establishment of immunodeficiency. This study characterizes the immunological effects of HIV-2 envelope protein gp105, a virus which is associated with a slower rate of disease progression.
METHODS: The effects of recombinant baculovirus-expressed envelope proteins from HIV-IIIB HIV-1MN, HIV-2ROD and SIVmac251 on anti-CD3-stimulated peripheral blood mononuclear cells (PBMC) from healthy donors were evaluated by incorporation of 3H-thymidine, flow cytometric analysis of bromodeoxyuridine incorporation in different T cell subsets, kinetics of expression of costimulatory molecules (CD40L/OX40) and assessment of cell death by annexin V/propidium iodide staining. The effects on production of tumour necrosis factor alpha (TNF-alpha) by monocytes were assessed at the single-cell level after a 6 h culture of unstimulated PBMC.
RESULTS: HIV-2 gp105 was more inhibitory than HIV-1 gp120 of T cell proliferation and the upregulation of CD40L and OX40; in the absence of signficant induction of apoptosis. This inhibition affected both CD4 and CD8 T cells and was only partially reversed by costimulation with interleukin 2 or CD28. gp105 strongly inducted TNF-alpha production by monocytes.
CONCLUSION: The immunosuppressive properties of the HIV envelope proteins could be beneficial rather than detrimental to the host by interfering with the heightened state of immunocellular activation that characterizes HIV infection and by limiting the bursts of viral replication. This hypothesis could in part explain the slower decline of CD4 cell numbers in HIV-2 infection and deserves further exploration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11125886     DOI: 10.1097/00002030-200012010-00007

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  10 in total

1.  Severe cholestatic hepatitis induced by pyritinol.

Authors:  Vasco Maria; Adriana Albuquerque; Ana Loureiro; Ana Sousa; Rui Victorino
Journal:  BMJ       Date:  2004-03-06

2.  HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients.

Authors:  Helena Skar; Pedro Borrego; Timothy C Wallstrom; Mattias Mild; José Maria Marcelino; Helena Barroso; Nuno Taveira; Thomas Leitner; Jan Albert
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

3.  Thymic HIV-2 infection uncovers posttranscriptional control of viral replication in human thymocytes.

Authors:  Helena Nunes-Cabaço; Paula Matoso; Russell B Foxall; Rita Tendeiro; Ana R Pires; Tânia Carvalho; Ana I Pinheiro; Rui S Soares; Ana E Sousa
Journal:  J Virol       Date:  2014-12-03       Impact factor: 5.103

Review 4.  Engineering broadly neutralizing antibodies for HIV prevention and therapy.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Adv Drug Deliv Rev       Date:  2016-01-29       Impact factor: 15.470

5.  Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection.

Authors:  Helena Barroso; Pedro Borrego; Inês Bártolo; José Maria Marcelino; Carlos Família; Alexandre Quintas; Nuno Taveira
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

6.  Insight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection.

Authors:  Suha Saleh; Lenard Vranckx; Rik Gijsbers; Frauke Christ; Zeger Debyser
Journal:  J Virus Erad       Date:  2017-01-01

7.  Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease.

Authors:  Rita Cavaleiro; António P Baptista; Rui S Soares; Rita Tendeiro; Russell B Foxall; Perpétua Gomes; Rui M M Victorino; Ana E Sousa
Journal:  PLoS Pathog       Date:  2009-11-20       Impact factor: 6.823

8.  HIV-2 and its role in conglutinated approach towards Acquired Immunodeficiency Syndrome (AIDS) Vaccine Development.

Authors:  Batul Diwan; Rupali Saxena; Archana Tiwari
Journal:  Springerplus       Date:  2013-01-11

9.  Single mutations in the transmembrane envelope protein abrogate the immunosuppressive property of HIV-1.

Authors:  Vladimir A Morozov; Alexey V Morozov; Marwan Semaan; Joachim Denner
Journal:  Retrovirology       Date:  2012-08-13       Impact factor: 4.602

Review 10.  Apoptosis of uninfected cells induced by HIV envelope glycoproteins.

Authors:  Barbara Ahr; Véronique Robert-Hebmann; Christian Devaux; Martine Biard-Piechaczyk
Journal:  Retrovirology       Date:  2004-06-23       Impact factor: 4.602

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.